Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.

This document is a corrigendum for an article titled "Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms." The corrigendum acknowledges errors in the legend for Figure 3 and Supplementary Table 1, which resulted in the omission of clarification regarding the calculation of objective response rates and complete response rates. The corrected legend and figures have been provided. Additionally, a correction has been made to a sentence in Section 3.2.3 regarding complete response rates. The authors apologize for the errors and state that they do not affect the scientific conclusions of the article. [Extracted from the article]